An observational study in Uterine Fibroid and Recurrence, sponsored by Wenwen Wang. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-31.
Sponsored by Wenwen Wang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Leiomyoma with a site in China — 20 open to participants now, 23 under way, 2 of them phase 3. Leiomyoma · China.
Among the 40 studies in Leiomyoma with a site in China, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2024, is one of 11 observational ones, reaches primary completion later than 2 of the 22 other live ones, and was the 22nd registered.
439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →20 of the 40 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:
Catherin Zhang · Sites in China
Ages 18–75 · Women only
Peking University Aerospace Center Hospital · Sites in China
Women only
Shenzhen Kangzhe Biotechnology Co., Ltd. · Sites in China
Ages 18–50 · Women only
Zhejiang University · Sites in China
Ages 18–65 · Women only
Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 3
First in 2008; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,200 is above the median of 150 across 107 observational studies indexed under Leiomyoma.
Median enrollment 120 across the 29 interventional studies, 200 across the 11 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 40 have an industry lead sponsor. The 10 most frequent:
Wenwen Wang is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Wenwen Wang has 3 studies filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Leiomyoma with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT06828419Second Affiliated Hospital of Wenzhou Medical UniversityA Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery | 2026-12-31 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT05840042Wenwen WangEpidemiology and Risk Factors of Uterine Fibroids in China | 2026-12-31 |
| NCT05386615InSightecPost-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 40 studies in Leiomyoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To research risk factors for recurrence of uterine fibroids and build a prediction model of recurrence of uterine fibroids to facilitate the early detection as well as the early intervention for patients who are prone to recur.
Uterine fibroids are the most common benign tumors of female reproductive organs during childbearing age. With the emphasis on fertility preservation and the pursuit of the physical integrity, about 46% of patients prefer the conservative surgery which preserves the uterus. However, the high recurrence rate of uterine fibroids after conservative surgery does cause formidable clinical problems.
According to the literature, the recurrence rate is about 11.7% at one year after myomectomy and would increase steadily. At the eighth year of myomectomy, the recurrence rate is as high as 84.4%. During the long-term follow-up, about one-third of patients eventually require reoperation.
Recurrence not only leads to the recurrence of fibroid-related symptoms such as anemia, abdominal and pelvic pain, frequent urination and urgency, abnormal stool, etc., but also increases the burden of economic and national medical insurance, besides, it even causes serious problems such as psychological disorders, infertility, adverse pregnancy outcomes and malignant transformation, which affecting physical and mental health as well as destroying family happiness and threatening national population security.
Female patients with uterine fibroids and accept myomectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Complete the observation and follow-up, to identify the outcome (recur or not recur).
Other: No intervertion
This study is a retrospective observational study without intervention.
The performance of the prediction model for recurrence of uterine fibroids as assessed by AUC
Complete the follow-up, and compare the actual recurrence population with the predicted recurrence population to judge the performance of the prediction model. Use the AUC (Area Under Curve)
Time frame: through study completion, about June.2025
Numbers of risk factors of recurrent uterine fibroids as certained by statistic analysis
To identify the risk factors of recurrent uterine fibroids. We identify the risk factors through statistic analysis. Statistical significance proves to be the symbol of identifycation of risk factors.
Time frame: about June.2024
The recurrence rate of uterine fibroids yearly
To calculate the recurrence rate of uterine fibroids yearly
Time frame: about Febrary.2024
The fertility rate after myomectomy
To research the fertility rate after myomectomy and evaluate the impact of the surgery.
Time frame: about Febrary.2024
The quality of life after myomectomy will be assessed by UFS-QOL,(uterine fibroid symptom and health-related quality of life, UFS-QOL)
To assess the quality of life after myomectomy, we use UFS-QOL.The UFS-QOL, the most popular self-administered instrument in assessing the whole spectrum of fibroid-related symptoms and health-related quality of life among patients with uterine fibroids, was designed in 2002s by James B et.al. Consisting of eight symptom items and twenty-nine health-related quality of life (HRQL) items of six subscales (concern, activities, energy/mood, control, self-consciousness, and sexual functioning), UFS-QOL is scored with a 5-point scale which demonstrates the patient' state of past 3 months. The final score (range, 0-100) is transformed based on a specific formula. Usually, a higher symptom severity score means more severe symptoms while a higher HRQL score indicates more perfect health
Time frame: through study completion, about June.2025
The degree of abdominal pain after myomectomy will be assessed by VAS(visual analogue scale, VAS)
VAS is the most commonly used one-dimensional measure of pain intensity. The scale consists mainly of a 100 mm straight line with one end indicating "completely painless" and the other end indicating "the most severe pain imaginable" or "extremely painful", etc. Patients will be asked to mark the line at the appropriate location to represent the intensity of the pain they are experiencing at the time
Time frame: through study completion, about June.2025
The blood loss will be assessed by PBLAC (Pictorial Blood Loss Assessment Chart (PBLAC)
The Pictorial Blood Loss Assessment Chart (PBLAC) proposed by Higham JM in 1990 is widely used internationally to evaluate menstrual flow. 1 Menstrual blood loss chart The menstrual blood loss chart is given different scores according to the different degrees of blood staining of each sanitary napkin: mild (1 point), the blood stained area \< 1/3 of the whole sanitary napkin; Moderate (5 points): The blood stained area accounts for 1/3\~3/5 of the whole sanitary napkin; Severe (20 points): The blood-stained area is basically the entire sanitary napkin.
Time frame: through study completion, about June.2025
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2024; primary completion for Jan 2025, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.